<DOC>
	<DOCNO>NCT00292422</DOCNO>
	<brief_summary>This Phase 2a study design evaluate safety tolerability multiple subcutaneous ( SC ) dose BG9924 , administer cohort dose-escalation fashion , patient active rheumatoid arthritis ( RA ) inadequate response therapy disease-modifying anti rheumatic drug ( DMARDs ) may undergo anti-TNF therapy . This study assist dose selection plan Phase 2 study .</brief_summary>
	<brief_title>Dose-Escalating Study BG9924 Combination With Methotrexate Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Must give write informed consent . If require local law , candidate must also authorize release use protect health information ( PHI ) . Male female subject age 18 75 year old , inclusive , time informed consent give . Must diagnosis RA Functional Class IIII accord 1987 Revised American Rheumatism Association Criteria Classification Rheumatoid Arthritis least 6 month prior baseline . Must treat MTX ( &gt; =10 mg/week &lt; =25 mg/week ) least 3 month immediately prior enrollment . The dose MTX must stable least 4 week prior Day 0 . Must active disease Screening define SJC &gt; =5 ( 66 joint count ) TJC &gt; =5 ( 68 joint count ) . All DMARDs , MTX hydroxychloroquine sulfate , must withdraw least 4 week prior Day 0 ( 8 week infliximab , adalimumab , leflunomide ) . Male female subject childbearing potential must willing practice effective birth control duration study . Female subject must : ( 1 ) postmenopausal least 12 month , ( 2 ) surgically sterile , ( 3 ) willing use 2 document form birth control ( e.g. , barrier spermicide , intrauterine device barrier spermicide , birth control pill barrier spermicide ) . Subjects must willing able complete plan study procedure . Subjects history malignancy carcinoma situ ( subject history excise treat basal cell carcinoma eligible participate study ) . Moles lesion currently undiagnosed , suspicious malignancy . Subjects history clinically significant ( determined Investigator ) cardiac , allergic , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal hematologic insufficiency major disease . Subjects rheumatic autoimmune disease RA , significant systemic involvement secondary RA ( include limit vasculitis , pulmonary fibrosis Felty 's syndrome ) . Secondary Sjögren 's syndrome permit . Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within 3 month prior Day 0 . History recurrent significant infection . Primary secondary immunodeficiency ( history currently active ) . History tuberculosis positive purify protein derivative ( PPD ; positive Mantoux test define ³10 mm induration [ size raise bump , redness ] ) test screen period . Subjects whose PPD induration &gt; =5 mm &lt; 10 mm eligible study negative chest Xray screen period . Fever ( body temperature &gt; 38°C ) symptomatic viral infection bacterial infection within 2 week prior Day 0 . Receipt live vaccine within 4 week prior Day 0 . Clinically significant chest Xray abnormality within 3 month prior Screening . Current prior treatment 1 antiTNF agent ( etanercept , infliximab , adalimumab ) approve investigational biologic agent treatment RA . Previous treatment antia4 integrin antibody within last 6 month . AntiTNF therapy infliximab adalimumab within 8 week etanercept within 4 week prior Day 0 . Treatment another investigational drug within 3 month prior Day 0 within 5 halflives agent , ever longer . If subject previously receive celldepleting therapy , relevant cell count must return normal . Subjects exclude meet follow criterion regard treatment concomitant therapy RA : Concomitant use oral steroid exceed 10 mg/day prednisone ( equivalent dose ) , 10 mg/day less , administer stable dose least 4 week prior Day 0 . Concomitant use NSAID administer stable dose least 2 week prior Day 0 . Concomitant use hydroxychloroquine sulfate &gt; 400 mg/day administer stable dose 4 week prior Day 0 . Concomitant use antiarthritic treatment , include approve experimental oral topical agent , within 4 week prior Day 0 . Intraarticular corticosteroid injection within 4 week prior Day 0 . Previous exposure BG9924 . Subjects exclude underwent surgical procedure , include bone/joint surgery/synovectomy ( include joint fusion replacement ) , within 12 week prior baseline plan procedure within 16 week randomization . Subjects laboratory test result Screening consider clinically significant ( determined Investigator ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal ( ULN ) establish central laboratory Platelet count &lt; 150,000/μL Hemoglobin &lt; 8.5 g/dL Neutrophil count &lt; 1.510^3/μL Positive hepatitis C virus ( HCV ) , hepatitis B surface antigen ( HBsAg ) , human immunodeficiency virus ( HIV ; recognize HIV test may permit site ) . Nursing mother , pregnant woman woman plan become pregnant study . Blood donation ( 1 unit ) within 1 month prior screen . History drug alcohol abuse ( determine Investigator ) within 1 year prior Day 0 . Current enrollment investigational drug study . Previous participation study . Subjects expect unavailable duration trial , likely noncompliant protocol , felt unsuitable Investigator/Sponsor reason . Other unspecified reason , opinion Investigator/Sponsor , make subject unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Antirheumatic Agents</keyword>
</DOC>